Skip to main content
. Author manuscript; available in PMC: 2023 Oct 20.
Published in final edited form as: N Engl J Med. 2022 Jun 5;387(6):495–505. doi: 10.1056/NEJMoa2203478

Figure 2. Kaplan–Meier Analysis of Response Duration and of Progression-free and Overall Survival.

Figure 2.

Panel A shows the duration of response to teclistamab therapy in the 104 patients who had an overall response (partial response or better) among the 165 patients who received the recommended phase 2 weekly dose of 1.5 mg per kilogram of body weight. Panel B shows progression-free survival in the overall population. Disease progression was assessed by an independent review committee on the basis of the criteria of the International Myeloma Working Group. Panel C shows overall survival among the 165 patients. Tick marks indicate censored data. NE denotes not estimable.